Clinical Trial

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

Name: A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity — clinical trial record (NCT07728383)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.

Trial Details

NCT Number	NCT07728383
Lead Sponsor	Gila Therapeutics, Inc.
Conditions	Obesity & Overweight
Enrollment	40 participants
Start Date	2026-06-17
Primary Completion	2027-05 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-27